Actively Recruiting
Evaluating Monthly and Weekly Extended-Release Buprenorphine Injections for Opioid Use Disorder Through a Mobile Pharmacy Clinic
Led by Yale University · Updated on 2026-10-09
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the acceptability and feasibility of using monthly extended-release subcutaneous buprenorphine BRIXADI XR-B to treat opioid use disorder OUD among people receiving care through a mobile pharmacy clinic. This pilot study focuses on persons interested in starting monthly or weekly injections of XR-B for their OUD treatment. The study is a Phase 4 interventional trial led by Yale University to evaluate this approach in a community setting. Participants will have shared decision-making with clinicians to choose either weekly or monthly injections of XR-B, based on their medical needs. The medication will be provided free of charge for six months through the nations first mobile pharmacy clinic offering this service. Medical visit information and medical record data will be collected throughout the six-month period to assess the feasibility of delivering XR-B in this manner. During the study, participants will receive regular medical visits for up to six months while using the XR-B injections. Researchers will collect data on retention of XR-B treatment at month six as the primary outcome. The study monitors participants medical status and gathers medical records to evaluate treatment acceptability and feasibility in this community-based approach.
CONDITIONS
Brief Title
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Research Team
S
Sandra Springer, MD
A
Angela Di Paola
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here